Document is current
Any future updates will be listed below
-
Authors
,
Deming, Yuetiva http://orcid.org/0000-0001-7512-5703
,
Dumitrescu, Logan
Barnes, Lisa L.
Thambisetty, Madhav
Kunkle, Brian
Gifford, Katherine A.
Bush, William S.
Chibnik, Lori B.
Mukherjee, Shubhabrata
De Jager, Philip L.
Kukull, Walter
Huentelman, Matt
Crane, Paul K.
Resnick, Susan M.
Keene, C. Dirk
Montine, Thomas J.
Schellenberg, Gerard D.
Haines, Jonathan L.
Zetterberg, Henrik
Blennow, Kaj
Larson, Eric B.
Johnson, Sterling C.
Albert, Marilyn
Moghekar, Abhay
del Aguila, Jorge L.
Fernandez, Maria Victoria
Budde, John
Hassenstab, Jason
Fagan, Anne M.
Riemenschneider, Matthias
Petersen, Ronald C.
Minthon, Lennart
Chao, Michael J.
Van Deerlin, Vivianna M.
Lee, Virginia M.-Y.
Shaw, Leslie M.
Trojanowski, John Q.
Peskind, Elaine R.
Li, Gail
Davis, Lea K.
Sealock, Julia M.
Cox, Nancy J.
Goate, Alison M.
Bennett, David A.
Schneider, Julie A.
Jefferson, Angela L.
Cruchaga, Carlos
Hohman, Timothy J.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (T32MH014877)
National Institutes of Health (R01 AG048015, K01 AG049164)
German Federal Ministry of Education and Research National Genome Research Network (01GS08125)
National Institute on Aging (P50 AG005146, P50 AG016574, P30 AG010161, P30 AG010124)
- License Information
-
More Information
Article History
Received: 1 May 2018
Revised: 26 June 2018
Accepted: 27 June 2018
First Online: 2 July 2018
Compliance with ethical standards
:
: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
: Dr. Larson reports royalties from UpToDate. Dr. Schneider reports personal fees from Avid Radiopharmaceuticals, personal fees from Navidea Biopharmaceuticals, outside the submitted work. Dr. Zetterberg has served at advisory boards of Eli Lilly, Roche Diagnostics and Pharmasum Therapeutics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Blennow has served at advisory boards of Alzheon, BioArctic, Eli Lilly, IBL International, Fujirebio, Merck, and Roche Diagnostics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.
